Molecular profiling of clear-cell renal cell carcinoma and prediction of response to targeted therapies against the vascular endothelial growth factor receptor, immune checkpoint inhibitors and mTOR inhibitors in the metastatic setting. KU Leuven
Over the last 10 years, several new therapies became available for the treatment of metastaticclear-cell kidney tumors: blood vessel inhibitors, mTOR-inhibitors and new generation
immunotherapy. Although these therapies have globally improved therapeutic outcome, individual
patient responses are highly variable. There is an urgent need to know in advance which therapy
will be the best for each patient in order to improve ...